www.fdanews.com/articles/176924-daiichi-sankyo-halts-late-stage-trial-for-lung-cancer-candidate
![](https://www.fdanews.com/ext/resources/test/Device_Images/blue-chest-xray.jpg?t=1463021369&width=430)
Daiichi Sankyo Halts Late-Stage Trial for Lung Cancer Candidate
June 6, 2016
Daiichi Sankyo pulled the plug on a Phase 3 trial of its non-small cell lung cancer candidate after an independent data monitoring committee found it missed its primary endpoint.
The committee recommended that Daiichi Sankyo discontinue the second Phase 3 study because patritumab failed to show clinically relevant tumor growth control in an initial Phase 3 trial.
The company plans to release the data from the analysis at an upcoming scientific meeting, a spokeswoman said. After further review of this analysis, Daiichi Sankyo will determine next steps for patritumab.